ONCODES.PREC.MED. EO-34
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease. It also focuses on the development of a rad… Read more
ONCODES.PREC.MED. EO-34 (ZR8) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ONCODES.PREC.MED. EO-34 (ZR8) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ONCODES.PREC.MED. EO-34 - Net Assets Trend (None–None)
This chart illustrates how ONCODES.PREC.MED. EO-34's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ONCODES.PREC.MED. EO-34 (None–None)
The table below shows the annual net assets of ONCODES.PREC.MED. EO-34 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ONCODES.PREC.MED. EO-34's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ONCODES.PREC.MED. EO-34 Competitors by Market Cap
The table below lists competitors of ONCODES.PREC.MED. EO-34 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
1 Production Film Co.
TWO:8458
|
$4.67K |
|
Viet Brand Invest JSC
VN:ABR
|
$4.67K |
|
Nishat Mills Ltd
KAR:NML
|
$4.67K |
|
TXN
WAR:TXN
|
$4.67K |
|
Juhayna Food Industries
EGX:JUFO
|
$4.66K |
|
27N0
XETRA:27N0
|
$4.66K |
|
Charoen Pokphand Foods PCL
STU:CPOF
|
$4.65K |
|
MICROVISION (MVIN.SG)
STU:MVIN
|
$4.65K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ONCODES.PREC.MED. EO-34's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ONCODES.PREC.MED. EO-34's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ONCODES.PREC.MED. EO-34 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ONCODES.PREC.MED. EO-34's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ONCODES.PREC.MED. EO-34 (ZR8) | €- | N/A | N/A | $4.66K |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |